Martinez-Leal et al, Supplementary Material 1

1. Martinez-Leal et al, Supplementary Material 1 Type of tumor (# cases) 15q21 7q35 14q32 p53 (17p13) PTEN (10q23) pRB (13q14) BRCA2 (13q12) Hepatocellular carcinoma (48) 45,83 91,67 60,42 79,17 70,83 You et al, 2004 Bladder carcinoma (51) 39,22 Natrajan et al, 2003 HNSCC (22) 62 88 Beder et al, 2003 Cervical carcinomas (67) 27 8 18 11 Kersemekers et al, 1998 Ovarian tumor (LMP) (50) 19,4 11,5 2,8 5,2 Nakayama et al, 2001 Ovarian tumor (OC) (23) 8,3 22,2 15,3 12,5 Nakayama et al, 2001 Endometrial AC (37) 24 26,09 18,18 5,56 Sirchia et al, 2000 Oropharyngeal EC (25) 50 18,7 47 13,3 46,7 Grati et al, 2000 Renal CC (45) 38 Alimov et al, 2004 Renal CC (19 primary tumors) 58 Alimov et al, 2004 Renal CC (6 metastases) 66 Alimov et al, 2004 Gliomas (142) 20 Dichamp et al, 2004 Glioblastoma multiforme (21) >40 >50 >50 >50 >50 Hu et al, 2003 Neuroblastoma (170) 18 Van Limpt et al, 2003 Nasopharyngeal C (60) >30 >30 43 Shao et al, 2002 The genes identified in our loss of function screening are in chromosome locations involved in significative (>20%) allelic loss in different tumors, according to data obtained in a CGH tumor database (see table 1, in supplementary information 2). Csn2 is located at 15q21.2 locus. Loss of this region is frequently observed in a variety of tumors of different origins, having a higher incidence in lung, breast, brain and colorectal carcinomas. The average incidence of loss (26.99%) is in the range observed for well known tumor suppressors such as pRB (38.64%), PTEN (30.68%) or BRCA2 (24.01%). This observation is in agreement with the existence of a candidate tumor suppressor gene in the 15q21.2 locus. This hypothesis is further supported with more detailed cytogenetic studies using microsatellite probes to detect specific LOH. Frequency of loss ranges from 27% in cervical carcinomas to 62% in head and neck squamous cell carcinomas (HNSCC) . Aldose reductase gene is located at 7q35. This region has a lower incidence of loss in tumors, still being significant in some tumors such as HNSCC (22.22%) (see supplementary information 3). LOH analysis show higher impact, specially in oropharingeal epithelial carcinoma, with a 50% of allelic loss (see table 2, in supplementary information). A similar situation accounts for BRF1, at 14q32.33. CGH analysis shows a moderate loss, with a higher incidence (20.69%) in colorectal carcinomas. LOH data confirms this observation, giving higher values of allelic loss (up to 66% in metastatic renal carcinoma) and affecting a variety of tumor types.